Autopsy findings.
1. Introduction
Deaths anaphylaxis related have always been very difficult in objectification in autopsies. So they are object of study for pathologists and legal doctors. In this work we want to propose a methodological protocol based on the various available diagnostic tools to use when an anaphylaxis related death is suspected.
2. Pathogenesis
The anaphylaxis is an allergic reaction. An allergic reaction is a spontaneous and exaggerate reaction of the body to a particular substance. These substances, called allergens, cause production of antibodies when enter the body. The exposition with the substance happens by inhalation, ingestion, contact or inoculation of the allergen. Every substance can act as allergen. Among the more frequent substances we remember the heterologous proteins (hormone like insulin, vasopressin, parathormon; enzymes like trypsin, chemotrypsin, penicillinases; pollens, food like eggs, fish, hazel-nuts, cereals, beans, chocolate; antiserums, hymenoptera venom); polysaccharides (iron dextran); drugs (antibiotics like penicillins, cephalosporins, Amphotericin B, nitrofurantoin, local anesthetics like procaine and lidocaine; vitamins like thiamine and folic acid); diagnostic substances (iodated means of contrast, sodium dehydrocoled, sulfobromoftaleine); industrial chemical products (ethylene oxide). (Fauci et al., 2009)
The concept of anaphylaxis comes from the study of the actinotoxins on the dogs’ arterial blood pressure (Richet, 1902).
It is well known that the anaphylactic shock is an example of the immediate type of hypersensitivity reaction inducing a diffuse organ hypoperfusion. It has been defined (Delage & Irey, 1972) as the failure of the peripheral circulation induced by an antigen (allergen)-antibody reaction in already sensitized subjects for a foreign substance. Whenever the hypoperfusion is complicated by increased capillary permeability, a rapidly irreversible circulatory fatal damage occurs (anaphylactic death).
Delage and Irey (Delage & Irey, 1972), in their clinico-pathological study of 43 validated cases of drug-induced fatal anaphylactic shock, the predominant role of penicillin, subsequently confirmed (Di Maio & Di Maio 2001; Menchel et al., 1987; Weeden, 1988), is reported. In these as well as in other cases immunoglobulin E (IgE) antibodies have been tested to various allergens, present in contrast media (Di Maio & Di Maio 2001; Lang et al., 1995; Pumphrey & Roberts, 2000; Risgaard et al., 2008), sera (Vance & Strassmann, 1942; Johann-Liang et. Al., 2011), insect venom (Pumphrey, 2000; Riches et al., 2001; Yunginger et al., 1991), and food (Di Maio & Di Maio 2001; Pumphrey, 2000; Pumphrey & Roberts, 2000; Yunginger et al., 1991) are thought to initiate anaphylactic reaction in patients previously sensitized towards that allergen (often unknowingly).
A register including all fatal anaphylactic reactions in the UK is operative since 1992 (Pumphrey, 2008). In France and Belgium since 2001 a university research team has founded the Allergy Vigilance Network, that in addition to reporting cases of severe anaphylaxis, to determine the prevalence of sensitization to risk allergens and screening and long-term monitoring of dangers related to new foods, ingredients and adjuvant sensitizing factors, with the French National Institute for Food Safety (AFSSA) and the Ministry of Consumer Affairs (DGCCRF) and various patient associations, also analyzes dangers related to the allergenicity of natural and modified food proteins (Moneret-Vautrin et al., 2002; Moneret-Vautrin, 2007).
Allergy depends on the individual “predisposition”. In certain people the contact between the allergen and the human body causes an abnormal immune reaction that clinically appears with the wide spectrum of manifestations of the allergic reaction (Crane, 2006; Liccardi et al., 2006)
Hypersensitivity reaction can be classified according the four type of immuno-pathological reaction of Gell and Coombs (Fauci, 2009):
type I: they are the result of an IgE-mediated reaction that leads to an immediate hypersensitivity
type II: IgG or IgM mediated. These antibodies are directed against cellular surface’s antigens altered by the drug that provoke a complement-mediated cytotoxicity.
type III: immuno-complexes mediated. The immunocomplexes’ dimensions determine the site of deposition and the consequent immunological damage.
type IV: retarded hypersensitivity. They come out by the interaction of the antigen with T lymphocyte and determine a cell-mediated reaction.
Type I reaction is characterized by a rapid activation (in few minutes)of vasoactive and spasmogen substances by antibodies that are on the surface of the mastcells and basophils. It’s composed of three phases:
sensitization, when the immune system come into contact with the allergen for the first time and stimulates IgE antibodies by B cells (the IgE production is under the control of TH2 CD4+ that increases its production and under the control of TH1 that reduces the production). The IgE bind mastcells’ and basophils’ receptors making them sensible to a next exposition to the antigen.
initial reaction: Immune system has a memory; so at the second exposition to the allergen there’s a binding between the antigen and the IgE antibodies localized on the mast-cells and basophils (sensitized). High affinity receptors (IgE) are almost exclusively on the mast-cells and on the basophils while low affinity receptors are also in other cytotypes (eosinophils, macrophages, platelets).
When the allergen binds to the high affinity receptor there’s the activation of the mastcells that leads to the degranulation of the mastcells and release of primary mediators (preformed) such as histamine, adenosine, chemiotactic mediators (e.g. the ones for the eosinophils), enzyme (tryptases, kynases), proteoglicans. There’s also the release of secondary mediators of ‘de novo’ synthesis such as leucothrienes, prostaglandines, platelets’ aggregation stimulation factors, cytokines, chemokines. In the first 30-60 minutes after exposition symptoms happen. Histamine is characterized by a very short half-life in the circulation, tryptase and chymase, are stable post-mortem (Edston et al., 2007; Nishio et al., 2005) and respectively used in post-mortem diagnosis of acute anaphylaxis (Edston, 2007; Nishio, 2005; Pumphrey, 2000; Riches et al., 2001; Schwartz, 1987; Yunginger et al., 1991). Tryptase is a serine protease stored mainly in mast cell granules, not found in circulating basophils, eosinophils, platelets or any other cell, represented by two varieties: an active free form () and an inactive tetramere () (Ansari et al., 1993; Schwartz et al. 1995).
The former is a protein released from mast cell granules during anaphylactic reactions, the latter is a similar protein secreted by resting mast cells and raised in mastocytosis (Pumphrey & Roberts, 2000; Schwartz et al. 1995).
Chymase is a mast cell-derived serine protease, characterized as an angiotensin II-generating enzyme (Nishio, 2005) and used to determine mast cells and thus to assess the timing of wounds after deaths (Bonelli et al., 2003; Urata et al., 1990).
It is quite stable in serum and a significant positive correlation between serum chymase and tryptase levels was found in post-mortem diagnosis of anaphylaxis (Nishio, 2005). Heterogeneity of human mast cells is known (Irani & Schwartz, 1994; Weidner & Austen, 1993) and recently different subsets of mast cells (MC) are distinguished by immunohistochemistry (Perskvist & Edston, 2007), as follows:
MC-TCs (formerly connective tissue mast cells) mainly composed of histamine, heparin, tryptase, chymase, cathepsin G and carboxypeptidase, preformed and stored in granules.
MC-T (formerly mucosal mast cells) lacking or containing only small amounts of chymase, carboxypeptidase and cathepsin.
MC-C lacking tryptase and not further characterized
Late phase: after 2 hours from the initial response the presence of antigen is not necessary and the tissue infiltration begins by inflammatory cells (neutrophils, eosinophils, basophils, monocytes) with consequent tissue lesions (in particular epithelia and mucosas).
This is the typical allergic reaction that usually brings to vasodilatation, skin rash, edema, itching; but the clinical spectrum is very wide and the allergic disturbs can be poor or get the death for anaphylactic shock.
Anaphylaxis is the most dangerous among the allergic reaction and it is a severe systemic reaction, with an often sudden and important beginning, with an acute response that happens in a variable time from few seconds to few minutes after the antigen exposition.
Anaphylaxis can be elicited for every concentration of the antigen (also minimal, sometimes it happens during skin test for drugs, etc.) (Bernstein et al., 2004; Blanton & Sutphin, 1949; Eleuterio Gonzàlez et al., 1997; Harris & Sure, 1950; Liccardi et al., 2006; Lockey et al., 1987; Riezzo, 2010; Weber-Mani & Pichler, 2008).
The typical anaphylaxis consists of sudden weakness, itching and urticaria, chest oppression, respiratory distress (wheezing) followed by cardio-circulatory collapse. Symptoms maybe very variable and could be involved almost all the functions/apparatus.
Could be involved: cardio-vascular system(tachycardia, hypotension, arrhythmias, ischemia/ myocardial infarction, heart arrest, symptoms from hypoperfusion are constant), nervous system (vertigo, asthenia, syncope, convulsions), eye (conjunctival injection, lachrymation), upper airway (nasal congestion, sneezing, hoarseness, stridor, pharyngeal or laryngeal edema, cough, obstruction, laryngospasm), lower airway (dyspnea, bronchospasm, tachypnea, involvement of the accessory respiratory muscles, cyanosis, respiratory arrest), skin (rash, erythema, itching, urticaria or urticarial reaction, edema, maculo-papular rash), gastrointestinal apparatus (nausea, vomiting, abdominal pain, diarrhea)(Crane et al. 2006; Fauci, 2009; Rovere-Querini, 2010).
Lethal cases are mainly due to: acute respiratory distress derived by the glottis edema or by bronchial obstruction/bronchospasm; cardio-vascular collapse also without an important respiratory distress.
In the lethal cases between the contact with the allergen and the anaphylaxis there’s a very short time. The anaphylaxis shows immediately or in few minutes after the exposition; in the most of the cases by 15-20 minutes. Reactions after 60 minutes from the exposition are very rare. As soon the reaction occurs as easier the death is; sometimes death can be immediate and, however by 1-2 hours. More rarely death occurs by 24 hours.
3. Proposal of a methodological protocol
In most of the cases the diagnosis of anaphylactic death represents a challenging deal. So it’s very important that the anatomo-pathological and/or medico-legal investigations must be very scrupulous and must analyze:
medical history of the deceased and eventual investigations on the spot;
necropsy with:
lab tests, for which it’s better to use peripheral blood sample and not central ones;
histological tests
histochemical and immuno-histochemical tests.
3.1. Medical history and investigations on the spot
To make diagnosis of anaphylactic death it’s important to make a correlation between the symptoms and an insect bite, the ingestion of food, drugs or other substances.
So we should collect anamnesis by family and general practitioner, especially if related to an history of allergy. Some patients, however, doesn’t know to have allergies and anaphylaxis is the first (and last) allergic reaction they have in their life.
Especially in the cases with medical history negative for past allergic reaction it’s important, when possible, going on the spot where the death occurred to get the eventual syringes used for injection and/ or to evaluate the presence of nests of wasps. It’s important hearing to witnesses that could tell the symptoms of the victim. Sudden weakness, itching and urticaria, chest oppression and respiratory distress (wheezing) followed by cardio-circulatory collapse may occur. Symptoms maybe very variable and could be involved almost all the functions/apparatus as we remembered before.
3.2. Complete necroscopic exam
It’s very important beginning with an accurate external exam to verify the presence of signs such as rash, urticaria or angioedema; to verify the skin integrity finding out eventual site of inoculation: it’s important to investigate also the sites covered by hair. If there a positive finding it’s opportune to proceed, during the successive autopsy, also to get a skin sample after the examination of the route in the case of subcutaneous or intramuscular injection. During the autopsy the pathological findings are often aspecific.
Usually we find multivisceral congestion, aspecific finding in various different types of death. (Barnard, 1967; Da Broi & Moreschi, 2011; Delage & Irey, 1972; Di Maio & Di Maio, 2001; Edston & van Hage-Hamsten, 2005; James & Austen, 1964; Low & Stables, 2006; Lu et al., 2006; Menchel et al, 1987; Pumphrey & Roberts, 2000; Shen et al.,2009; Yilmaz et al., 2009).
You can find:
glottis edema and/or of the pharyngo-laryngeal districts;
congestion and/or pulmonary edema;
hyperinflation of the alveoli with acute emphysema;
endo-luminal bronchial secretions- this finding is more frequent if there’s an asthmatic factor and it’s usually related to a almost immediate death;
hemorrhagic petechiae: it’s suggestive of an asphyxial component of the death and it’s usually associated with an almost immediate death.
These findings can change according to the allergen type, to the way of administration and to the time passed between the exposition and the death (Edston & van Hage-Hamsten, 2005; Low & Stables, 2006; Pumphrey & Roberts, 2000). If the death is very fast the only macroscopic finding is an important multivisceral congestion associated or not with the petechial hemorrhages (Edston & van Hage-Hamsten, 2005; Low & Stables, 2006; Pumphrey & Roberts, 2000; Roberts & Pumphrey, 2001).
In the table n. 1 there are the results of different studies present in literature (Barnard, 1967; Delage & Irey, 1972; Greenberger et al, 2007; James & Austen, 1964; Low & Stables, 2006; Pumphrey & Roberts, 2000; Shen et al.,2009; Yilmaz et al., 2009).
Autopsy findings | Study | |||||||||
Delage & Irey (1972) | James & Austen (1964) | Barnard (1967) | ||||||||
Number of cases | 40 | 6 | 50 | |||||||
3 cases penicillin, 1 case guinea-pig haemoglobin; 1 case bee venom; 1 case ragweed extraxt | Insect-Stings | |||||||||
Erythematous skin rash/cutaneous edema | 35 | |||||||||
Pulmonary congestion and edema | 36 | 5 | 35 | |||||||
Upper airway edema | 15 | 4 | 14 | |||||||
Hyperinflation of the lungs and/or mucous plugging of airways | 18 | 5 | 16 | |||||||
Petechial hemorrahages | 10 | |||||||||
Autopsy findings | Study | |||||||||
Pumphrey & Roberts (2000) | Low & Stables (2006) | |||||||||
Number of cases | 56 | 18 | ||||||||
Venom (19) | Food (16) | Drugs (21) | Venom (4) | Food (2) | Drugs (10) | Undetermined (2) | ||||
Erythematous skin rash/cutaneous edema | 1 | 2 | 0 | 0 | 0 | 0 | 2 | |||
Pulmonary congestion and edema | 14 | 9 | 18 | 3 | 0 | 5 | 2 | |||
Upper airway oedema | 6 | 10 | 7 | 3 | 0 | 0 | 1 | |||
Hyperinflation of the lungs and/or mucous plugging of airways | 7 | 5 | 3 | |||||||
Petechial hemorrahages | 4 | 5 | 1 | |||||||
Autopsy findings | Study | |||||||||
Greenberger et al. (2007) | Shen et al. (2009) | Yilmaz et al. (2009) | ||||||||
Number of cases | 25 | 28 | 36 | |||||||
Erythematous skin rash/cutaneous edema | 3 | 4 | 2 | |||||||
Pulmonary congestion and edema | 18 | 28 | 29 | |||||||
Upper airway edema | 16 | 15 | 11 | |||||||
Hyperinflation of the lungs and/or mucous plugging of airways | 3 | 11 | 5 | |||||||
Petechial hemorrahages | 6 | 3 |
A complete autopsy, with histo-pathological and chemical-toxicological investigations, is mandatory in every case.
3.3. Laboratory tests
A very useful first investigation is the research of the total and specific IgE for specific substances: The Igs are very stable also after death (Hieda et al, 1991).
The finding of total IgE doesn’t demonstrate the anaphylaxis but indicates that the subject was sensible for particular substances (e.g. insect venom, antibiotics, etc..). However, in there’s a positive history or suspect for allergies for specific substances, every suspected substance must be tested with specific IgE. If there isn’t an accurate anamnesis or an history of allergy it’s a good idea testing the most common allergens. (Calvani et al., 2007; Hamilton & Adkinson, 2003; Horn et al., 2004).
A second investigation on the cadaverous blood sample is the dosage of beta-tryptase. As we already said, the degranulation of the mast-cells releases powerful chemical mediators (histamine, tryptase, etc..) (Ansari et al., 1993, Carson et al., 2009; Way & Baxendine 2002).
The tryptases, instead, are relatively stable post-mortem (values can remain high for some days in a serum sample kept at room temperature and for some months if freezed) (Joint Task Force on Practice Parameters et al., 1998; Horn, 2004) and their dosage is very useful in the diagnostics of acute anaphylaxis. As already said, in addition to mast cells also the basophiles produce tryptases but fewer than 300-700 times compared to skin and lung mast cells. So the serum concentration of tryptase is considered an index of mast cells activation. In particular we must determine the beta-tryptases that are usually released by mast cell degranulation (while the alfa-tryptase is secreted constitutively by mast cells and represent an index of the mast cells mass and so it is present in the mastocytosis) (Kanthawatana et al, 1999; Schwartz 2004).
For this reason the ratio between total tryptase (alfa + beta) and beta-tryptase is important to distinguish between an episode of anaphylaxis and patients with systemic mastocytosis: a ratio less than 10 is usually indicative of an anaphylactic reaction while a ratio <20 suggests a systemic mastocytosis (Joint Task Force on Practice Parameters et al., 2005; Lieberman et al, 2010; Schwartz et al., 1995, Schwartz & Irani, 2000). Serum levels of tryptase quickly increase and are detectable by 30 minutes (the concentration peak is reached in the first 2-3 hours) and remain high for about 5 hours (Joint Task Force on Practice Parameters et al., 2005; Lieberman et al, 2010). High levels of beta-tryptase point out a degranulation and, so, support the diagnosis of anaphylaxis.
Usually the increase of the serum level of tryptase is bigger as much as the anaphylaxis has been severe. It’s important underline that the negativity of this test doesn’t exclude an anaphylactic death. In fact Sampson has demonstrated that the rise of this enzyme could be absent in the anaphylaxis by food, maybe because of the involvement of other cells such as basophils or monocytes/macrophages (Sampson et al., 1992).
Therefore tryptase concentrations in femoral blood (not influenced by position at death or resuscitation efforts) (Edston et al., 2007) and serum chymase and tryptase levels (Nishio et al., 2005; Shen et al., 2002) have been suggested in postmortem cases to validate the diagnosis of anaphylactic deaths.
The histamine is another product of mast cell degranulation. This mediator, even if is very valid in vivo (it’s an index of mast cell activation even though not specific of the mastcells alone), isn’t an effective indicator after death because has a very short half-life (2 minutes).
So the N-methylhistamine, that is a product of histamine degradation and is stable in the urine, but in the cases of anaphylactic death the time is too short to find it into the urine (Sthephan et al. 1990; Edston et al, 2005, 2007).
Among the other possible tests we remember the serum titration of a mastcell-specific chymase (Nishio et al., 2005; Osawa et al. 2008), that is a serum protein mainly kept into the mastcell granules.
It’s important to note that the positivity to total IgE or of the serum tryptase cannot be considered, by the forensic profile, as a sure indication of a death by anaphylaxis because the positivity of one or both the markers has been found also in other pathologies (Randall et al., 1995; Horn et al., 2004) such as traumatic death or the sudden infant death syndrome (Buckley et al., 2001; Edston et al., 1999; D’Errico et al., 2008; Holgate et al, 1994; Nishio & Suzuki, 2004; Schwartz, 2001) but must be integrated with the results of other investigations that must be done in every case of death.
3.4. Histology
Finally the histo-pathological diagnosis is very important and may show eosinophilia (Delage ande Irey, 1972) especially in the upper and lower airway, in the liver and in the spleen (Voigt, 1966); the presence of glottis edema and/or pharyngo-laryngeal edema that, histologically, could be associated with a wide dissociation of collagen fibers and of the glandular elements, eosinophilic infiltration and vascular congestion (Pumphrey and Roberts, 2000).
Sometimes, using hematoxylin-eosin stain, there’s lung hyperinflation with emphysema, endo-luminar mucous and peri-bronchial congestion, edema and eosinophilic infiltrate.
Another method is the mast cell count in the various organs and tissues: unfortunately specific stainings for mast-cells are based on the metachromatic properties of the cytoplasmic granules and showed limited:
the positivity of the mast cells varies according the technique used to fix and stain (Strobel et all., 1981);
the counts in the tissue ‘post-mortem’ after the anaphylaxis is underestimated because of the mast cells’ degranulation during anaphylaxis. The staining can’t put in evidence the degranulated mast cells; so, because the number of mast cells varies from each one it’s impossible decide how many cells have degranulated.
the base –level of mast-cell concentration after death is strongly underestimated.
In literature, however, there is a case (Heard et all., 1989) where the authors compare the pulmonary concentration of mast-cells in the allergic subject pre- (biopsy) and post-mortem showing a diminution in the latter sections.
3.5. Auxiliary techniques: histochemical and immuno-histochemical
Since histology alone cannot give absolute results, it have been studied more complex techniques such as histochemistry and immuno-histochemistry.
In 1960 Glenner and Cohen (Glenner & Cohen, 1960) identified the proteases of mast cell granules using histo-chemical procedures. The main morphologic characteristic to distinguish mast cells is the presence, in cytoplasm, of many roundish granules, homogeneous in man, soluble in water, that stain methacromatically with basic dyes such as Toluidine blue, or with dyes for glycosaminoglycans polymerized such as Alcian blue. The granules are coated with membrane and contain heparin and histamine. In particular, the presence of heparin, an anticoagulant glycosaminoglycan, accounts for the staining of these granules. In the anaphylaxis the massive degranulation could be emphasized with this technique with the highlight of the granules next to mast cells. Furthermore it has been identified antibodies against histamine but they are not useful for post-mortem evaluation since histamine is poorly stable (Johansson et al., 1992)
Pagoda red stain is another histo-chemical procedure successfully employed for the histological demonstration of several substances with fibrillar periodical structure, like amyloids (Battaglia et al., 1985; Yanagihara et al. 1984), cellulose, siloxanes, polysiloxanes and polyethylene polymers and more rarely to put in evidence eosinophilia in various tissues (Kyono et al, 1982). This technique displays a mixing of cytotypes, contemporaneously on the same slide, easily identifiable, since degranulated mast cells and their outside granules appear brilliant red over a pale blue background (Trani et al., 2008).
++ | - | - | - | +++ | |
- | +++ | +++ | - | +++ |
Pagoda Red stain is a dye originally employed in the industrial field to dye clothes and occasionally carried out in cytopathology in case of nasal (Rivasi & Bergamini, 1988) or ocular (Rivasi et al., 1992) allergic processes possibly related to the presence of airborne, nonhuman elements.
Immuno-histo-chemical investigations although more expensive than histo-chemical ones allow to characterize the immuno-phenotype of the various cells in the inflammatory infiltrate associated with anaphylaxis; especially specific antibodies can bind superficial antigens in these cells such as tryptases and chymases (Akin et al. 2007; Carson & Cook, 2009; Irani et al., 1989; Perskvist & Edston, 2007).
Human mast cell tryptases comprise a family of trypsin-like neutral serine proteases that are predominantly expressed in mast cells. This antibody is useful for the identification of very atypical or immature mast cells (MC) in mast cell leukemia, and for the detection of small, even minute, dense focal MC infiltrates in staging procedures in patients with known cutaneous mastocytosis. Using an avidin-biotin enhanced immunoperoxidase procedure, with monoclonal antibodies (AA1, AA3, and AA5) directed against human mast cell tryptase, it’s possible to obtain an intense staining of mast cells in paraffin-embedded tissue. It represents an highly specific and sensitive means for the detection of mast cells in routinely processed tissues.
Chymases belong to a family of serine proteases like intracellular granule and it’s involved in regulating extracellular matrix proteolysis and promoting tissue remodelling (Doggrell & Wanstall, 2004). This substance is mainly found in mast cell cytoplasm but also outside the mast cells in the connective tissues surrounding vascular walls and, in less concentration, in basophils. (Hamada et al. 1999). Chymase antibodies is available for formaldehyde-fixed tissue and can be used simultaneously to tryptase by a sandwich technique applying the two antibody (Buckley et al. 1999).
The eosinophilic major basic protein, also known as MBP, PRG2, a proteoglycan 2, BMPG or bone marrow natural killer cell activator, is a constituent of the eosinophilic granules. High levels of the pro-EMBP are present in pregnancy serum and in placenta where it develops a complex with other proteins. It may influence antiparasitic defense mechanisms as cytotoxin and helminthotoxin and immune hypersensitivity reactions (Trocme et al. 1989).
The role of EMBP is to modulate inflammation and lead to tissue destruction resulting in cytotoxic effects (Butterworth & David, 1981). It has been demonstrated to be elicited in mast cell and basophil (Trocme et al. 1989) degranulation.
4. Conclusions
Post-mortem diagnosis of anaphylactic death is very difficult and it’s possible only excluding every other cause of death and taking into considerations the results of other exams: accurate medical history, complete necroscopic examination integrated with histological examination, lab tests, and auxiliary techniques of histochemistry and immuno-histo-chemistry. This diagnosis, in particular for the medico-legal aspect, cannot be based on the positivity of one only type of investigation (e.g. bioumoral tests) because that positivity can be found also in other pathologies (Horn, 2004) but must be integrated with the results of more investigations.
Acknowledgments
Many thanks to Aldo Ferrucci and Mr Vidic for their kind patience and to everyone that supported the authors in writing this chapter.
References
- 1.
Akin C. Scott L. M. Kocabas C. N. Kushnir-Sukhov N. Brittain E. Noel P. Metcalfe D. D. 2007 Demonstration of an aberrant mast-cell population with clonal markers in a subset of patients with ‘‘idiopathic’’ anaphylaxis.110 7 2331 2333 0006-4971 - 2.
Ansari M. Q. Zamora J. L. Lipscomb M. F. 1993 Postmortem diagnosis of acute anaphylaxis by serum tryptase analysis: a case report.99 1 101 103 0002-9173 - 3.
Barnard J. H. 1967 Allergic and pathologic findings in fifthy insect-sting fatalities. ,40 2 107 114 0021-8707 - 4.
Battaglia S. Barbolini G. Botticelli A. R. Trentini G. P. 1985 Apoptotic amyloid: a study on prostatic amyloidosis with particular reference to corpora amylacea.3 1-2 105 114 0252-1172 - 5.
Bernstein D. I. Wanner M. Borish L. Liss G. M. The Immunoteraphy. Committee of. the American. Academy of. Allergy Asthma. Immunology 2004 The Immunoteraphy Committee of the American Academy of Allergy, Asthma and Immunology. Twelve-year survey of fatal reactions to allergen injections and skin testing: 1990-2001.113 6 1129 1136 0091-6749 - 6.
Blanton W. B. Sutphin A. K. 1949 Death during skin testing. ,217 2 169 173 0002-9629 - 7.
Bonelli A. Bacci S. Norelli G. A. 2003 Affinity cytochemistry analysis of mast cells in skin lesions: a possible tool to assess the timing of lesions after death.117 6 331 334 0937-9827 - 8.
Buckley M. G. Mc Euen A. R. Walls A. F. 1999 The detection of mast cell subpopulations in formalin-fixed human tissues using a new monoclonal antibody specific for chymase. ,189 1 138 143 0022-3417 - 9.
Buckley M. G. Variend S. Walls A. F. 2001 Elevated serum concentrations of beta- tryptase, but not alpha-tryptase in Sudden Infant Death Syndrome: investigation of anaphylactic mechanisms.31 11 1696 1704 ISNN 0954-7894 - 10.
Butterworth A. E. David J. R. 1981 Eosinophil function. ,304 3 154 156 0028-4793 - 11.
Calvani M. Cardinale F. Martelli A. Muraro M. A. Pucci N. Savino F. 2007 Springer-Verlag Italia,978-8-84700-620-1 Milano, Italia - 12.
Carson H. J. Cook B. A. 2009 Mast cell tryptase in a case of anaphylaxis due to repeat antibiotic exposure. ,11 5 234 236 ISNN 1344-6223 - 13.
Crane J. von Mutius. E. Custovic A. 2006 Epidemiology of allergic disease. In: Holgate ST, Church MK, Lichtenstein LM, eds, 3rd ed. Mosby Elsevier,233 246 Elsevier Ltd.,0-32303-227-3 U.K. - 14.
Da Broi. U. Moreschi C. 2011 Post-mortem diagnosis of anaphylaxis: a difficult task in forensic medicine.204 1-3 1 5 0379-0738 - 15.
D’Errico S. Neri M. Riezzo I. Rossi G. Pomara C. Turillazzi E. Fineschi V. 2008 Beta-tryptase and quantitative mast-cell increase in a sudden infant death following hexavalent immunization.179 2-3 25 29 0379-0738 - 16.
Delage C. Irey N. S. 1972 Anaphylactic deaths: a clinicopathologic study of 43 cases,17 4 525 540 0022-1198 - 17.
Di Maio V. J. Di Maio D. 2001 , second ed., CRC Press,084930072 Boca Raton, USA - 18.
Doggrell S. A. Wanstall J. C. 2004 Vascular chymase: pathophysiological role and therapeutic potential of inhibition.61 4 March (2004),653 662 0008-6363 - 19.
Edston E. Eriksson O. Van Hage M. 2007 Mast cell tryptase in postmortem serum-reference values and confounders,121 4 275 280 0937-9827 - 20.
Edston E. Gidlund E. Wickman M. Ribbing H. van Hage-Hamsten M. 1999 Increased mast cell tryptase in sudden infant death syndrome--anaphylaxis,hypoxia or artefact?29 12 1648 1654 ISNN 0954-7894 - 21.
Edston E. Van Hage-Hamsten M. 2005 Diagnosis of Anaphylaxis in: ,3 part. 6, Tsokos, M.,267 281 Humana Press,978-1-59259-910-3 Totowa, New Jersey - 22.
Eleuterio Gonzàlez. J. Leal de Hernàndez. L. Gonzàlez Spencer. D. 1997 Anaphylactic reaction caused by the performance of skin tests: report of a case.44 3 May-97),74 76 0002-5151 - 23.
Fauci A. S. Barunwald E. Kasper L. Hauser S. L. Longo D. L. Jameson J. L. Loscalzo J. 2009 Anafilassi, In: Mc Graw Hill,114 115 978-8-83862-462-9 Milano, Italy - 24.
Glenner G. G. Cohen L. A. 1960 Histochemical demonstration of a species-specific trypsin-like enzyme in mast cells.185 846 847 0028-0836 - 25.
Greenberger P. A. Rotskoff B. D. Lifschultz B. 2007 Fatal anaphylaxis: postmortem findings and associated comorbid diseases.98 3 252 257 1081-1206 - 26.
Hamada H. Terai M. Kimura H. Hirano K. Oana S. Nimi H. 1999 Increased expression of mast cell chymase in the lungs of patients with congenital heart disease associated with early pulmonary vascular disease.160 4 1303 1308 0107-3449 X - 27.
Hamilton R. G. Adkinson N. F.jr 2003 Clinical and laboratory assessment of IGE-dependent hypersensitivity.111 2 suppl., (03),687 701 1534-4436 - 28.
Hard B. E. Nunn A. J. Kay A. B. 1989 Mast cells in human lungs157 1 59 63 0022-3417 - 29.
Harris M. C. Shure N. 1950 Sudden death due to allergy tests. ,21 3 208 216 0021-8707 - 30.
Hieda Y. Kageura M. Hara K. Kashimura S. 1991 Postmortem changes in hapten- specific IgE antibody responses in mice.104 3 133 135 0937-9827 - 31.
Holgate S. Waiters C. Walls A. F. Lawrance S. Shell D. J. Variend S. Fleming P. J. Berry P. J. Gilbert R. E. Robinson C. 1994 The anaphylaxis hypothesis of sudden infant death syndrome (SIDS): mast cell degranulation in cot death revealed by elevated concentrations of tryptase in serum. ,24 12 1115 1122 0954-7894 - 32.
Horn K. D. Halsey J. F. Zumwalt R. E. 2004 Utilization of serum tryptase and immu- noglobulin E assay in the postmortem diagnosis of anaphylaxis.25 1 37 43 0195-7910 - 33.
Irani A. M. Bradford T. R. Kepley C. L. Schechter N. M. Schwartz L. B. 1989 Detection of MCT and MCTC types of human mast cells by immunohistochemistry using new monoclonal anti-tryptase and anti-chymase antibodies37 10 1509 1515 0022-1554 - 34.
Irani A. M. Schwartz L. B. 1994 Human mast cell heterogeneity. ,15 6 November-94),303 308 1046-9354 - 35.
James L. P. Austen K. F. 1964 Fatal systemic anaphylaxis in man.270 597 603 0028-4793 - 36.
Johann-Liang R. Josephs S. Dreskin S. C. 2011 Analysis of anaphylaxis cases after vaccination: 10-year review from the national vaccine injury compensation.106 5 440 443 1534-4436 - 37.
Johansson O. Virtanen M. Hilliges M. Yang Q. 1992 Histamine immunohistochemistry: a new and highly sensitive method for studying cutaneous mast cells. .24 5 283 287 0018-2214 - 38.
Joint Task Force on Practice Parameters, American Academy of Allergy, Asthma and Immunology, American College of Allergy, Asthma and Immunology, and the Joint Council of Allergy, Asthma and Immunology. 1998 The diagnosis and management of anaphylaxis.101 465 528 ISNN 0091-6749 - 39.
Joint Task Force on Practice Parameters; American Academy of Allergy, Asthma and Immunology; American College of Allergy, Asthma and Immunology; Joint Council of Allergy, Asthma and Immunology. 2005 The diagnosis and management of anaphylaxis: an updated practice parameter.115 3 suppl. 2, (05),483 523 ISNN 0091-6749 - 40.
Kanthawatana S. Carias K. Arnaout R. Hu J. Irani A. M. Schwartz L. B. 1999 The potential clinical utility of serum alpha-protryptase levels.103 6 1092 1099 0091-6749 - 41.
Kiyono J. Tada T. Wakabayashi T. Kishimoto H. Nitta M. 1982 Eosinophile granule staining with Dylon. .30 10 1137 1141 0047-1860 - 42.
Lang D. M. Alpern M. B. Visintainer P. F. Smith S. T. 1995 Gender risk for anaphylactoid reaction to radiographic contrast media. ;95 4 813 817 0091-6749 - 43.
Liccardi G. D’Amato G. Canonica G. W. Salzillo A. Piccolo A. Passalacqua G. 2006 Systemic reactions from skin testing: literature review, ,16 2 75 78 1018-9068 - 44.
Lieberman P. Nicklas R. A. Oppenheimer J. Kemp S. F. Lang D. M. Bernstein D. I. Bernstein J. A. Burks A. W. Feldweg A. M. Fink J. N. Greenberger P. A. Golden D. B. James J. M. Kemp S. F. Ledford D. K. Lieberman P. Sheffer A. L. Bernstein D. I. Blessing-Moore J. Cox L. Khan D. A. Lang D. Nicklas R. A. Oppenheimer J. Portnoy J. M. Randolph C. Schuller D. E. Spector S. L. Tilles S. Wallace D. 2010 The diagnosis and management of anaphylaxis practice parameter: 2010 update. .126 3 477 480 0091-6749 - 45.
Lockey R. F. Benedict L. M. Turkeltaub P. C. Bukantz S. C. 1987 Fatalities from immunotherapy and skin testing. .79 4 660 677 0091-6749 - 46.
Low I. Stables S. 2006 Anaphylactic deaths in Auckland, New Zealand: a review of coronial autopsies from 1985 to 2005.38 4 328 332 0031-3025 - 47.
Lu P. Bao C. S. Wang L. X. 2006 Analysis on 27 autopsy cases died of anaphylactic shock induced by mainline.22 4 305 306 1004-5619 - 48.
Menchel S. M. Gorevic P. D. Adkinson N. F. 1987 An immunologic approach to the evaluation of deaths due to penicillin anaphylaxis, , San Diego, 87 - 49.
Moneret-Vautrin D. A. 2007 Allergic risk and role of the Allergy Vigilance Network,191 4-5 April-07),807 814 0001-4079 - 50.
Moneret-Vautrin D. A. Kanny G. Parisot L. 2002 First survey from the "Allergy Vigilance Network": life-threatening food allergies in France.34 6 194 198 0397-9148 - 51.
Nishio H. Takai S. Miyazaki M. Horiuchi H. Osawa M. Uemura K. Yoshida K. Mukaida M. Ueno K. Suzuki K. 2005 Usefulness of serum mast cell-specific chymase levels for postmortem diagnosis of anaphylaxis.119 6 331 334 0937-9827 - 52.
Nishio H. Suzuki K. 2004 Serum tryptase levels in sudden infant death syndrome in forensic autopsy cases.139 1 57 60 0379-0738 - 53.
Osawa M. Satoh F. Horiuchi H. Tian W. Kugota N. Hasegawa I. 2008 Postmortem diagnosis of fatal anaphylaxis during intravenous administration of therapeutic and diagnostic agents: evaluation of clinical laboratory parameters and immunohistochemistry in three cases. .10 3 143 147 1344-6223 - 54.
Perskvist N. Edston E. 2007 Differential accumulation of pulmonary and cardiac mast-cell-subsets and eosinophils between fatal anaphylaxis and asthma death. A postmortem comparative study.169 1 43 49 0379-0738 - 55.
Pumphrey R. S. H. Roberts I. S. 2000 Postmortem findings after fatal anaphylactic reactions. .53 4 273 276 0021-9746 - 56.
Pumphrey, R.S.H 2000 Lessons for management of anaphylaxis from a study of fatal reactions.30 8 1144 1150 0954-7894 - 57.
Pumphrey R. S. H. 2008 Fatal Anaphylaxis in the UK, 1992-2001, in Anaphylaxis: Novartis Foundation Symposium 257 (eds G. Bock and J. Goode),116 132 John Wiley & Sons, Ltd,978-0-47086-119-6 Chichester, UK - 58.
Randall B. Butts J. Halsey J. F. 1995 Elevated postmortem tryptase in the absence of anaphylaxis.40 2 208 211 0022-1198 - 59.
Riches K. J. Gills D. James R. A. 2002 An autopsy approach to bee sting-related deaths. ;34 3 257 262 0031-3025 - 60.
Richet C. 1902 Des effets anaphylactiques de l’actinotoxine sur la pressi on artérielle, . 54,837 838 - 61.
Riezzo I. Bello S. Neri M. Turillazzi E. Fineschi V. 2010 Ceftriaxone intradermal test-related fatal anaphylactic shock: a medico-legal nightmare.65 1 130 131 0105-4538 - 62.
Risgaard O. Søe C. K. Zejden A. 2008 Lethal reaction after contrast medium administration.170 17 1474 0041-5782 - 63.
Rivasi F. Bergamini G. 1988 Nasal cytology in allergenic processes and other syndromes caused by hyperreactivity.4 2 99 105 8755-1039 - 64.
Rivasi F. Cavallini G. M. Longanesi L. 1992 Cytology of allergenic conjunctivitis. Presence of airbone, non human elements.36 4 July-92),492 498 0001-5547 - 65.
Roberts I. S. D. Pumphrey R. S. H. 2001 The autopsy in fatal anaphylaxis. In19 Lowe, D.G.; Underwood J.C.E.,145 162 Churchill Livingstone,0-44306-347-8 U.K. - 66.
Rovere-Querini P. 2010 Anafilassi, In: C. Rugarli.,1632 1633 Elservier,8-82143-109-6 Italy - 67.
Sampson H. A. Mendelson L. Rosen J. P. 1992 Fatal and near-fatal anaphylactic reactions to food in children and adolescents.327 6 380 384 0028-4793 - 68.
Schwartz L. B. 1987 Mediators of human mast cells and human mast cell subsets. .58 4 226 235 0003-4738 - 69.
Schwartz L. B. 2000 Effector cells of anaphylaxis: mast cells and basophils.257 65 74 pp. (65-74),1528-2511 - 70.
Schwartz L. B. 2001 Light is recognized best through darkness: mast cells and Sudden Infant Death Syndrome.31 11 1657 1659 ISNN 0954-7894 - 71.
Schwartz L. B. Irani A. M. 2000 Serum tryptase and the laboratory diagnosis of systemic mastocytosis.14 3 641 657 0889-8588 - 72.
Schwartz L. B. Sakai K. Bradford T. R. Ren S. Zwelman B. Worobec A. S. Metcalfe D. D. 1995 The alpha form of human tryptase is the predominant type present in blood at base line in normal subjects and is elevated in those with systemic mastocytosis.96 6 2702 2710 0021-9738 - 73.
Shen Y. Li L. Grant J. Rubio A. Zhao Z. Zhang X. Zhou L. Fowler D. 2009 Anaphylactic death in maryland (United States) and Shangai (China): a rewiew of forensic autopsy cases from 2004 to 2006.186 1-3 1 5 0379-0738 - 74.
Shen Y. W. Lu C. Zhao Z. Q. 2002 Tryptase and fatal anaphylaxic reaction.18 3 132 134 1004-5619 - 75.
Stephan V. Zimmermann A. Kühr J. Urbanek R. 1990 Determination of N-methylhistamine in urine as an indicator of histamine release in immediate allergic reactions. .86 6 part 1, (90),862 868 0091-6749 - 76.
Strobel S. Miller H. R. Ferguson A. 1981 Human intestinal mucosal mast cells: evaluation of fixation and staining techniques.34 8 851 858 0021-9746 - 77.
Trani N. Bonetti Reggiani. L. Gualandri G. Barbolini G. 2008 Immediate anaphylactic death following antibiotics injection: splenic eosinophilia easily revealed by pagoda red stain. .181 1-3 21 25 0379-0738 - 78.
Trocme S. D. Kephart G. M. Allansmith M. R. Bourne W. M. Gleich G. J. 1989 Conjunctival deposition of eosinophil granule major basic protein in vernal conjunctivitis and contact lens-associated giant papillary conjunctivitis. ,108 1 57 63 0002-9394 - 79.
Urata H. Kinoshita A. Misono K. S. Bumpus F. M. Husain A. 1990 Identification of a highly specific chymase as the major angiotensin II-forming enzyme in human heart.265 36 22348 22357 0021-9258 - 80.
Vance B. M. Strassmann G. 1942 Sudden death following injection of foreign protein. ;34 849 865 - 81.
Voigt J. 1966 Eosinophils in the spleen in cases of lethal anaphylactic shock.6 3 162 163 0025-8024 - 82.
Way M. G. Baxendine C. L. 2002 The significance of post mortem tryptase levels in supporting a diagnosis of anaphylaxis.57 3 310 311 0003-2409 - 83.
Weber-Mani U. Pichler W. J. 2008 Anaphylactic shock after intradermal testing with betalactam antibiotics.63 6 785 0105-4538 - 84.
Weedn W. 1988 Anaphylactic death (Letters to the Editor),33 5 1108 1110 0022-1198 - 85.
Weidner N. Austen K. F. 1993 Heterogeneity of mast cells at multiple body site. Flurorescent determination of avidin binding and immunofluorescent determination of chymase, tryptase and carboxypeptidase content.189 2 156 162 0344-0338 - 86.
Yanagihara M. Mehregan A. H. Mehregan D. R. 1984 Staining of amyloid with cotton dyes.120 9 1184 1185 0000-3987 X - 87.
Yilmaz R. Yuksekbas O. Erkol Z. Bulut E. R. Arslan M. N. 2009 Postmortem findings after anaphylactic reactions to drugs in Turkey.30 4 346 349 0195-7910 - 88.
Yunginger J. W. Nelson D. R. Squillace D. L. Jones R. T. Holley K. E. Hyma B. A. Biedrzycki L. Sweeney K. G. Sturner W. Q. Schwartz L. B. 1991 Laboratory investigation of deaths due to anaphylaxis.36 3 857 865 0022-1198